CA2460917A1 - Anticorps du facteur tissulaire humain - Google Patents

Anticorps du facteur tissulaire humain Download PDF

Info

Publication number
CA2460917A1
CA2460917A1 CA002460917A CA2460917A CA2460917A1 CA 2460917 A1 CA2460917 A1 CA 2460917A1 CA 002460917 A CA002460917 A CA 002460917A CA 2460917 A CA2460917 A CA 2460917A CA 2460917 A1 CA2460917 A1 CA 2460917A1
Authority
CA
Canada
Prior art keywords
ffr
value
human
rfvlla
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460917A
Other languages
English (en)
Inventor
Per-Ola Freskgaard
Jes Thorn Clausen
Brit Binow Sorensen
Marianne Kjalke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460917A1 publication Critical patent/CA2460917A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anticorps totalement humains isolés provoquant une réaction immunitaire avec le facteur tissulaire (FT) humain pour inhiber le facteur de coagulation VIIa (FVIIa).
CA002460917A 2001-10-02 2002-09-30 Anticorps du facteur tissulaire humain Abandoned CA2460917A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101437 2001-10-02
DKPA200101437 2001-10-02
PCT/DK2002/000644 WO2003029295A1 (fr) 2001-10-02 2002-09-30 Anticorps du facteur tissulaire humain

Publications (1)

Publication Number Publication Date
CA2460917A1 true CA2460917A1 (fr) 2003-04-10

Family

ID=8160743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460917A Abandoned CA2460917A1 (fr) 2001-10-02 2002-09-30 Anticorps du facteur tissulaire humain

Country Status (15)

Country Link
EP (1) EP1434802A1 (fr)
JP (1) JP2005512970A (fr)
KR (1) KR20040045478A (fr)
CN (1) CN1575302A (fr)
BR (1) BR0213046A (fr)
CA (1) CA2460917A1 (fr)
CZ (1) CZ2004454A3 (fr)
HU (1) HUP0401658A2 (fr)
IL (1) IL160998A0 (fr)
MX (1) MXPA04003051A (fr)
NO (1) NO20041802L (fr)
PL (1) PL368989A1 (fr)
RU (1) RU2004113373A (fr)
WO (1) WO2003029295A1 (fr)
ZA (1) ZA200402303B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP1374896A4 (fr) * 2001-03-26 2005-04-06 Koji Suzuki Agents ameliorant la rheologie sanguine
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
JP2006516564A (ja) * 2003-01-22 2006-07-06 ノボ　ノルディスク　アクティーゼルスカブ Ｔｆ結合薬剤及びそれらの使用
KR20060035608A (ko) * 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
AU2004255553B2 (en) * 2003-06-19 2009-08-20 Genentech, Inc. Compositions and methods for treating coagulation related disorders
WO2005020927A2 (fr) * 2003-08-29 2005-03-10 Centocor, Inc. Procede permettant de stimuler la survie d'un greffon a l'aide d'anticorps anti-facteur tissulaire
WO2005079766A2 (fr) * 2004-02-20 2005-09-01 Novo Nordisk A/S Polytherapie
CA2914170C (fr) * 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Proteines de liaison interleukine 13
CN101423552B (zh) * 2008-02-29 2012-05-16 复旦大学 一种人源抗人组织因子Fab及其制备方法
AU2013203150B2 (en) * 2008-12-09 2016-09-22 Genmab A/S Human antibodies against tissue factor
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
AU2016277670B2 (en) * 2008-12-09 2019-02-07 Genmab A/S Human antibodies against tissue factor
WO2010131235A1 (fr) * 2009-05-15 2010-11-18 University Of The Free State Fragments d'anticorps inhibiteurs pour le facteur tissulaire humain
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
WO2017028823A1 (fr) * 2015-08-20 2017-02-23 复旦大学 Anticorps dirigé contre le facteur tissulaire, procédé de préparation associé et utilisation associée
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
EP3502141A4 (fr) * 2016-08-22 2020-04-08 Fudan University Anticorps ciblant le facteur tissulaire, son procédé de préparation et son utilisation
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
WO2019217455A1 (fr) 2018-05-07 2019-11-14 Genmab A/S Méthodes de traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un conjugué anticorps anti-facteur tissulaire-médicament
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
JP2779193B2 (ja) * 1989-02-02 1998-07-23 帝人株式会社 抗ヒト組織因子モノクローナル抗体
PT833911E (pt) * 1995-06-07 2004-09-30 Ortho Mcneil Pharm Inc Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
US6677436B1 (en) * 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
IL148980A0 (en) * 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
EP1263960A2 (fr) * 2000-03-16 2002-12-11 Genentech, Inc. Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore

Also Published As

Publication number Publication date
JP2005512970A (ja) 2005-05-12
ZA200402303B (en) 2004-11-25
KR20040045478A (ko) 2004-06-01
HUP0401658A2 (hu) 2004-11-29
PL368989A1 (en) 2005-04-04
WO2003029295A1 (fr) 2003-04-10
NO20041802L (no) 2004-04-30
IL160998A0 (en) 2004-08-31
RU2004113373A (ru) 2005-03-27
MXPA04003051A (es) 2004-07-05
BR0213046A (pt) 2005-06-28
CZ2004454A3 (cs) 2004-09-15
EP1434802A1 (fr) 2004-07-07
CN1575302A (zh) 2005-02-02

Similar Documents

Publication Publication Date Title
CA2460917A1 (fr) Anticorps du facteur tissulaire humain
ES2702365T3 (es) Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
AU780775B2 (en) Factor IX/factor IXa antibodies and antibody derivatives
KR100553629B1 (ko) 혈전증치료에유용한항응고제
AU2008351988B2 (en) Anti-properdin antibodies
US8293882B2 (en) Anti-tissue factor antibodies and compositions
AU2005243193B2 (en) Antibodies specific for glycoprotein VI and methods of producing these antibodies
JP2021121615A (ja) 第ＸＩＩａ因子のモノクローナル抗体阻害剤
CN109153726A (zh) 抗因子xi的活性位点的单克隆抗体及其用途
WO2004039842A2 (fr) Anticorps humanises anti-facteur tissulaire
JP2016519081A (ja) ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体
JP2004516236A (ja) 抗血栓剤
US9708410B2 (en) Anti-tissue factor antibodies and compositions
US20050169927A1 (en) Human tissue factor antibodies
US20140328846A1 (en) Anti-properdin antibodies
US20040001830A1 (en) Human tissue factor antibodies
US20050106139A1 (en) Humanized tissue factor antibodies
AU2002333213A1 (en) Human tissue factor antibodies
TW200407427A (en) Human tissue factor antibodies
HK40096491A (zh) 一种因子xiia的单克隆抗体抑制剂

Legal Events

Date Code Title Description
FZDE Discontinued